Plasma natriuretic peptides and incidence of subtypes of ischemic stroke

Cerebrovascular Diseases

Volumn 37, Issue 6, 2014, Pages 444-450

  Berntsson, John ^a   Zia, Elisabet ^a   Borné, Yan ^a   Melander, Olle ^a   Hedblad, Bo ^a   Engström, Gunnar ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Epidemiology; Natriuretic peptides; Stroke

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; MIDREGIONAL PRO ATRIAL NATRIURETIC PEPTIDE; UNCLASSIFIED DRUG; ATRIAL NATRIURETIC FACTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NATRIURETIC FACTOR; BIOLOGICAL MARKER;

ADULT; AGE; AGED; ARTICLE; BLOOD SAMPLING; BRAIN ISCHEMIA; CARDIOEMBOLIC STROKE; CARDIOVASCULAR RISK; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; LARGE ARTERY ATHEROSCLEROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REFERENCE VALUE; RISK ASSESSMENT; SEX RATIO; SMALL ARTERY OCCLUSION; ARTERY OCCLUSION; ATRIAL FIBRILLATION; BLOOD LEVEL; BODY MASS; BRAIN ATHEROSCLEROSIS; DIABETES MELLITUS; HYPERTENSION; PROPORTIONAL HAZARDS MODEL; SMOKING; TREATMENT DURATION; ATHEROSCLEROSIS; BLOOD; HEART FAILURE; MIDDLE AGED; PROSPECTIVE STUDY; RISK; RISK FACTOR; STROKE;

ADULT; AGED; ATHEROSCLEROSIS; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; FEMALE; HEART FAILURE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NATRIURETIC PEPTIDES; PROSPECTIVE STUDIES; RISK; RISK FACTORS; STROKE;

EID: 84904524363     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000363279     Document Type: Article

References (32)

1. Levin ER, Gardner DG, Samson WK: Natriuretic peptides. N Engl J Med 1998; 339: 321-328.
2. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K: ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J 2008; 29: 2388-2442.
3. Montaner J, Garcia-Berrocoso T, Mendioroz M, Palacios M, Perea-Gainza M, Delgado P, Rosell A, Slevin M, Ribo M, Molina CA, Alvarez- Sabin J: Brain natriuretic peptide is associated with worsening and mortality in acute stroke patients but adds no prognostic value to clinical predictors of outcome. Cerebrovasc Dis 2012; 34: 240-245.
4. Rost NS, Biffi A, Cloonan L, Chorba J, Kelly P, Greer D, Ellinor P, Furie KL: Brain natriuretic peptide predicts functional outcome in ischemic stroke. Stroke 2012; 43: 441-445.
5. Folsom AR, Nambi V, Bell EJ, Oluleye OW, Gottesman RF, Lutsey PL, Huxley RR, Ballantyne CM: Troponin T, N-terminal pro-B-type natriuretic peptide, and incidence of stroke: the atherosclerosis risk in communities study. Stroke 2013; 44: 961-967.
6. Khan SQ, Dhillon O, Kelly D, Squire IB, Struck J, Quinn P, Morgenthaler NG, Bergmann A, Davies JE, Ng LL: Plasma N-terminal B-type natriuretic peptide as an indicator of long-term survival after acute myocardial infarction: comparison with plasma midregional pro-atrial natriuretic peptide: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol 2008; 51: 1857-1864.
7. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P: N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005; 293: 1609-1616.
8. Kurl S, Ala-Kopsala M, Ruskoaho H, Makikallio T, Nyyssonen K, Vuolteenaho O, Sivenius J, Salonen JT, Laukkanen JA: Plasma Nterminal fragments of natriuretic peptides predict the risk of stroke and atrial fibrillation in men. Heart 2009; 95: 1067-1071.
9. Rutten JH, Mattace-Raso FU, Steyerberg EW, Lindemans J, Hofman A, Wieberdink RG, Breteler MM, Witteman JC, van den Meiracker AH: Amino-terminal pro-B-type natriuretic peptide improves cardiovascular and cerebrovascular risk prediction in the population: the Rotterdam study. Hypertension 2010; 55: 785-791.
10. Takahashi T, Nakamura M, Onoda T, Ohsawa M, Tanno K, Itai K, Sakata K, Sakuma M, Tanaka F, Makita S, Yoshida Y, Ogawa A, Kawamura K, Okayama A: Predictive value of plasma B-type natriuretic peptide for ischemic stroke: a community-based longitudinal study. Atherosclerosis 2009; 207: 298-303.
11. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS: Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350: 655-663.
12. Manjer J, Carlsson S, Elmståhl S, Gullberg B, Janzon L, Lindström M, Mattisson I, Berglund G: The Malmö Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants. Eur J Cancer Prev 2001; 10: 489-499.
13. Hedblad B, Nilsson P, Janzon L, Berglund G: Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a crosssectional study in Malmö, Sweden. Diabet Med 2000; 17: 299-307.
14. Jerntorp P, Berglund G: Stroke registry in Malmö, Sweden. Stroke 1992; 23: 357-361.
15. Ingelsson E, Arnlov J, Sundström J, Lind L: The validity of a diagnosis of heart failure in a hospital discharge register. Eur J Heart Fail 2005; 7: 787-791.
16. Smith JG, Platonov PG, Hedblad B, Engström G, Melander O: Atrial fibrillation in the Malmö Diet and Cancer Study: a study of occurrence, risk factors and diagnostic validity. Eur J Epidemiol 2010; 25: 95-102.
17. Zia E, Hedblad B, Pessah-Rasmussen H, Berglund G, Janzon L, Engström G: Blood pressure in relation to the incidence of cerebral infarction and intracerebral hemorrhage. Hypertensive hemorrhage: debated nomenclature is still relevant. Stroke 2007; 38: 2681-2685.
18. Di Serio F, Ruggieri V, Varraso L, De Sario R, Mastrorilli A, Pansini N: Analytical evaluation of the Dade Behring Dimension RxL automated N-terminal proBNP (NT-proBNP) method and comparison with the Roche Elecsys 2010. Clin Chem Lab Med 2005; 43: 1263-1273.
19. Morgenthaler NG, Struck J, Thomas B, Bergmann A: Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 2004; 50: 234-236.
20. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman- Breen C: Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005; 352: 2049-2060.
21. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS; CKD-EPI Investigators: Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012; 367: 20-29.
22. Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, Heurgren M, Olausson PO: External review and validation of the Swedish National Inpatient Register. BMC Public Health 2011; 11: 450.
23. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41.
24. Newton-Cheh C, Larson MG, Vasan RS, Levy D, Bloch KD, Surti A, Guiducci C, Kathiresan S, Benjamin EJ, Struck J, Morgenthaler NG, Bergmann A, Blankenberg S, Kee F, Nilsson P, Yin X, Peltonen L, Vartiainen E, Salomaa V, Hirschhorn JN, Melander O, Wang TJ: Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet 2009; 41: 348-353.
25. Smith JG, Newton-Cheh C, Almgren P, Struck J, Morgenthaler NG, Bergmann A, Platonov PG, Hedblad B, Engström G, Wang TJ, Melander O: Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. J Am Coll Cardiol 2010; 56: 1712-1719.
26. Tu HT, Campbell BC, Churilov L, Kalman JM, Lees KR, Lyden PD, Shuaib A, Donnan GA, Davis SM; VISTA collaborators: Frequent early cardiac complications contribute to worse stroke outcome in atrial fibrillation. Cerebrovasc Dis 2011; 32: 454-460.
27. Potpara TS, Lip GY: Ischemic stroke and atrial fibrillation - a deadly serious combination. Cerebrovasc Dis 2011; 32: 461-462.
28. Lip GY, Rasmussen LH, Skjoth F, Overvad K, Larsen TB: Stroke and mortality in patients with incident heart failure: the Diet, Cancer and Health (DCH) cohort study. BMJ Open 2012;2:e000975, doi: 10.1136/bmjopen- 2012-000975.
29. Costello-Boerrigter LC, Boerrigter G, Redfield MM, Rodeheffer RJ, Urban LH, Mahoney DW, Jacobsen SJ, Heublein DM, Burnett JC Jr: Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol 2006; 47: 345-353.
30. Lee SJ, Kim JH, Na CY, Oh SS: Eleven years' experience with Korean cardiac myxoma patients: focus on embolic complications. Cerebrovasc Dis 2012; 33: 471-479.
31. McCullough PA, Duc P, Omland T, McCord J, Nowak RM, Hollander JE, Herrmann HC, Steg PG, Westheim A, Knudsen CW, Storrow AB, Abraham WT, Lamba S, Wu AH, Perez A, Clopton P, Krishnaswamy P, Kazanegra R, Maisel AS: B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003; 41: 571-579.
32. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE: Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-2375.